ANI Pharmaceuticals (BSFA) Ratios
ANI Pharmaceuticals Ratios
DE:BSFA's free cash flow for Q2 2026 was $67.99M. For the 2026 fiscal year, DE:BSFA's free cash flow was increased by $11.32M and operating cash flow was $56.67M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.71 | 2.72 | 3.57 | 3.46 | 3.68 |
| Quick Ratio | 2.19 | 2.02 | 2.81 | 2.40 | 2.74 |
| Cash Ratio | 1.03 | 0.75 | 1.52 | 0.49 | 1.15 |
| Solvency Ratio | 0.19 | 0.06 | 0.18 | 0.03 | 0.01 |
| Operating Cash Flow Ratio | 0.67 | 0.33 | 0.82 | -0.31 | 0.04 |
| Short-Term Operating Cash Flow Coverage | 10.73 | 6.98 | 139.95 | -36.71 | 3.91 |
| Net Current Asset Value | $ -146.54M | $ -327.48M | $ 72.99M | $ -77.29M | $ -91.08M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.23 | 0.49 | 0.32 | 0.38 | 0.37 |
| Debt-to-Equity Ratio | 0.60 | 1.46 | 0.62 | 0.85 | 0.80 |
| Debt-to-Capital Ratio | 0.38 | 0.59 | 0.38 | 0.46 | 0.44 |
| Long-Term Debt-to-Capital Ratio | 0.36 | 0.59 | 0.38 | 0.46 | 0.44 |
| Financial Leverage Ratio | 2.66 | 3.00 | 1.98 | 2.25 | 2.15 |
| Debt Service Coverage Ratio | 5.09 | 2.50 | 3.80 | 1.38 | 1.30 |
| Interest Coverage Ratio | 4.05 | 0.03 | 1.74 | -1.26 | -3.34 |
| Debt to Market Cap | 0.21 | 0.58 | 0.29 | 0.44 | 0.50 |
| Interest Debt Per Share | 17.22 | 33.22 | 17.37 | 19.35 | 23.76 |
| Net Debt to EBITDA | 0.19 | 7.59 | 0.61 | 9.52 | 60.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 51.01% | 59.27% | 62.71% | 56.13% | 53.45% |
| EBIT Margin | 13.11% | -0.75% | 9.62% | -10.94% | -20.42% |
| EBITDA Margin | 23.46% | 10.27% | 21.90% | 7.91% | 1.44% |
| Operating Profit Margin | 9.20% | 0.10% | 9.65% | -11.15% | -18.41% |
| Pretax Profit Margin | 10.84% | -3.62% | 4.08% | -19.81% | -25.94% |
| Net Profit Margin | 8.87% | -3.01% | 3.86% | -15.14% | -19.71% |
| Continuous Operations Profit Margin | 8.87% | -3.01% | 3.86% | -15.14% | -19.71% |
| Net Income Per EBT | 81.78% | 83.39% | 94.50% | 76.43% | 76.00% |
| EBT Per EBIT | 117.93% | -3803.42% | 42.31% | 177.61% | 140.87% |
| Return on Assets (ROA) | 5.44% | -1.44% | 2.08% | -6.30% | -5.52% |
| Return on Equity (ROE) | 14.49% | -4.32% | 4.10% | -14.15% | -11.88% |
| Return on Capital Employed (ROCE) | 6.99% | 0.05% | 6.19% | -5.34% | -5.82% |
| Return on Invested Capital (ROIC) | 5.63% | 0.04% | 5.84% | -4.08% | -4.42% |
| Return on Tangible Assets | 8.72% | -2.72% | 2.81% | -9.97% | -9.48% |
| Earnings Yield | 4.95% | -1.73% | 1.89% | -7.32% | -7.34% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.14 | 2.77 | 3.00 | 1.91 | 1.68 |
| Payables Turnover | 6.91 | 5.48 | 4.95 | 4.74 | 4.38 |
| Inventory Turnover | 3.02 | 1.83 | 1.63 | 1.32 | 1.23 |
| Fixed Asset Turnover | 14.14 | 10.80 | 10.92 | 7.32 | 4.10 |
| Asset Turnover | 0.61 | 0.48 | 0.54 | 0.42 | 0.28 |
| Working Capital Turnover Ratio | 2.18 | 1.73 | 1.57 | 1.32 | 1.33 |
| Cash Conversion Cycle | 184.03 | 264.66 | 271.36 | 390.87 | 430.10 |
| Days of Sales Outstanding | 116.14 | 131.73 | 121.52 | 190.86 | 217.05 |
| Days of Inventory Outstanding | 120.68 | 199.53 | 223.60 | 277.08 | 296.37 |
| Days of Payables Outstanding | 52.79 | 66.60 | 73.76 | 77.07 | 83.32 |
| Operating Cycle | 236.82 | 331.26 | 345.12 | 467.94 | 513.42 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 9.24 | 3.31 | 6.61 | -1.92 | 0.26 |
| Free Cash Flow Per Share | 7.53 | 2.44 | 5.58 | -2.93 | -1.61 |
| Dividend Paid and CapEx Coverage Ratio | 5.22 | 3.45 | 5.91 | -1.73 | 0.14 |
| Capital Expenditure Coverage Ratio | 5.40 | 3.78 | 6.43 | -1.90 | 0.14 |
| Operating Cash Flow Coverage Ratio | 0.57 | 0.10 | 0.42 | -0.11 | 0.01 |
| Operating Cash Flow to Sales Ratio | 0.21 | 0.10 | 0.24 | -0.10 | 0.02 |
| Free Cash Flow Yield | 9.53% | 4.41% | 10.12% | -7.29% | -3.50% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 22.55 | -53.15 | 52.86 | -13.66 | -13.62 |
| Price-to-Sales (P/S) Ratio | 1.79 | 1.74 | 2.04 | 2.07 | 2.69 |
| Price-to-Book (P/B) Ratio | 2.93 | 2.49 | 2.17 | 1.93 | 1.62 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 10.49 | 22.69 | 9.88 | -13.73 | -28.57 |
| Price-to-Operating Cash Flow Ratio | 8.55 | 16.68 | 8.34 | -20.96 | 174.72 |
| Price-to-Earnings Growth (PEG) Ratio | -0.05 | 0.25 | -0.40 | 1.33 | -0.17 |
| Enterprise Value Multiple | 7.83 | 24.51 | 9.92 | 35.64 | 246.31 |
| Enterprise Value | 1.62B | 1.55B | 1.06B | 892.43M | 767.49M |
| EV to EBITDA | 7.83 | 24.51 | 9.92 | 35.64 | 246.31 |
| EV to Sales | 1.84 | 2.52 | 2.17 | 2.82 | 3.55 |
| EV to Free Cash Flow | 10.75 | 32.87 | 10.52 | -18.73 | -37.78 |
| EV to Operating Cash Flow | 8.76 | 24.17 | 8.89 | -28.60 | 231.03 |
| Tangible Book Value Per Share | -0.06 | -8.97 | 12.24 | 3.61 | 2.92 |
| Shareholders’ Equity Per Share | 26.96 | 22.18 | 25.42 | 20.82 | 28.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.17 | 0.06 | 0.24 | 0.24 |
| Revenue Per Share | 44.05 | 31.80 | 27.04 | 19.46 | 17.16 |
| Net Income Per Share | 3.91 | -0.96 | 1.04 | -2.95 | -3.38 |
| Tax Burden | 0.82 | 0.83 | 0.94 | 0.76 | 0.76 |
| Interest Burden | 0.83 | 4.82 | 0.42 | 1.81 | 1.27 |
| Research & Development to Revenue | 0.06 | 0.07 | 0.07 | 0.07 | 0.05 |
| SG&A to Revenue | 0.36 | 0.41 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.04 | 0.05 | 0.04 | 0.05 | 0.05 |
| Income Quality | 2.36 | -3.46 | 6.33 | 0.65 | -0.08 |
Currency in USD